WilliamJPaoMD

PubMed

• 50 citations
  Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensit...
  Naiyer A. Rizvi, Valerie W. Rusch, William Pao, Jamie E. Chaft, Marc Ladanyi, Vincent A. Miller, Lee M. Krug, Christopher G. Azzoli, Manjit S. Bains, Robert J. Downey,...> ;Clinical Cancer Research. 2011 May 15
• 2060 citations
  Somatic mutations affect key pathways in lung adenocarcinoma
  Li Ding, Gad Getz, David A. Wheeler, Elaine R. Mardis, Michael D. McLellan, Kristian Cibulskis, Carrie Sougnez, Heidi Greulich, Donna M. Muzny, Margaret Morgan, Lucind...> ;Nature. 2008 Oct 23
• 248 citations
  Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the add...
  Gregory J. Riely, Mark G. Kris, Binsheng Zhao, Tim Akhurst, Daniel T. Milton, Leslie B. Tyson, William Pao, Naiyer A. Rizvi, Lawrence H. Schwartz, Vincent A. Miller> ;Clinical Cancer Research. 2007 Sep 1
• 81 citations
  Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
  Daniel T. Milton, Gregory J. Riely, Christopher G. Azzoli, Jorge Gomez, Robert T. Heelan, Mark G. Kris, Lee M. Krug, William Pao, Barbara Pizzo, Naiyer A. Rizvi, Vince...> ;Cancer. 2007 Aug 1
• 600 citations
  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
  Gregory J. Riely, William Pao, Duy Pham, Allan R. Li, Naiyer A. Rizvi, Ennapadam Venkatraman, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi, Vincent A. Miller> ;Clinical Cancer Research. 2006 Feb 1
• 50 citations
  Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging.
  Stewart J. Kellie, F. Ann Hayes, Laura C. Bowman, Edward H. Kovnar, James W. Langston, Jesse J. Jenkins, William J. Pao, Raphael Ducos, Alexander A. Green> ;Cancer. 1991 Nov 1
• 3 citations
  Local-regional non-rhabdomyosarcomatous soft tissue sarcomas of the head and neck.
  James Fontanesi, Charles B. Pratt, Larry E. Kun, Omar Hustu, William J. Pao, Edwin C. Douglass, Irvin D. Fleming, Bhaskar N. Rao> ;International Journal of Radiation Oncology, Biology, Physics. 1990 Oct 1
• 44 citations
  Postoperative radiotherapy in the treatment of extremity soft tissue sarcomas.
  William J. Pao, Miljenko V. Pilepich> ;International Journal of Radiation Oncology, Biology, Physics. 1990 Oct 1
• 3 citations
  Wilms' tumor: Reduced-dose radiotherapy in advanced-stage Wilms' tumor with favorable histology
  Robert L. Tobin, A James Fontanesi, Larry E. Kun, Diane L. Fairclough, H. Omar Hustu, William J. Pao, Edwin C. Douglass, Judith A. Wilimas, A.P. Mahesh Kumar, Jesse J....> ;International Journal of Radiation Oncology, Biology, Physics. 1990 Oct 1
• 59 citations
  Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients.
  William J. Pao, H. Omar Hustu, Edwin C. Douglass, Neal S. Beckford, Larry E. Kun> ;International Journal of Radiation Oncology, Biology, Physics. 1989 Aug 1
• 10 citations
  Hodgkin’s Disease in Children
  Pao Wj, Kun Le> ;Hematology/oncology Clinics of North America. 1989 Jun 1
• Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
  Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., Ladanyi, M.> ;Clin Cancer Res. 2011 Mar 1
• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
  Miller, V. A., Kris, M. G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L. M., Pao, W., Rizvi, N., Pizzo, B., Tyson, L., Venkatraman, E., Ben-Porat, L., Memoli, ...> ;J Clin Oncol. 2004 Mar 15
• Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
  Zakowski, M. F., Hussain, S., Pao, W., Ladanyi, M., Ginsberg, M. S., Heelan, R., Miller, V. A., Rusch, V. W., Kris, M. G.> ;Arch Pathol Lab Med. 2009 Mar
• A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
  Milton, D. T., Azzoli, C. G., Heelan, R. T., Venkatraman, E., Gomez, J. E., Kris, M. G., Krug, L. M., Pao, W., Rizvi, N. A., Dunne, M., Miller, V. A.> ;Cancer. 2006 Sep 1
• Join now to see all